Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | NEOXpress, a novel TCR platform to target solid tumors

David Apelian • 29 Jun 2022

David Apelian, MD, PhD, BlueSphere Bio, Pittsburgh, PA, gives an overview of the mechanism of action of NEOXpress™, a patient-specific neoantigen discovery platform, and explains how it can be combined with TCXpress™, a high-throughput T-cell receptor (TCR) search and capture platform, to treat solid tumors. While NEOXpress™ captures the tumor’s neoantigen profile, TCXpress™ captures the TCR repertoire of a tumor sample. Together, this allows identifying multiple TCRs that can specifically recognize non-self neoantigens in a tumor, and thus engineer highly personalized T-cell receptor T-cells that can be re-infused into the patient. This interview was recorded via an online conference call with VJOncology.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.